Low‐dose chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab in follicular lymphoma

E-ISSN： 1600-0609|94|3|277-278

ISSN： 0902-4441

Source： EUROPEAN JOURNAL OF HAEMATOLOGY, Vol.94, Iss.3, 2015-03, pp. : 277-278

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Fludarabine, cyclophosphamide, and multiple‐dose rituximab as frontline therapy for chronic lymphocytic leukemia

CANCER, Vol. 121, Iss. 21, 2015-11 ,pp. : 3869-3876

John Wiley & Sons Inc

Access to resources Recommend Favorite

Immunochemotherapy with Rituximab, Vincristine and 5-Day Cyclophosphamide for Heavily Pretreated Follicular Lymphoma

Oncology, Vol. 68, Iss. 2-3, 2005-07 ,pp. : 146-153

Karger

Access to resources Recommend Favorite

Reduced‐dose fludarabine, cyclophosphamide, and rituximab (FCR‐Lite) plus lenalidomide, followed by lenalidomide consolidation/maintenance, in previously untreated chronic lymphocytic leukemia

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 6, 2015-06 ,pp. : 487-492

John Wiley & Sons Inc

Access to resources Recommend Favorite

Myelosuppression after frontline fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia

CANCER, Vol. 119, Iss. 21, 2013-11 ,pp. : 3805-3811

John Wiley & Sons Inc

Access to resources Recommend Favorite

Retreatment with rituximab offers a similar survival benefit as maintenance therapy in patients with low tumor burden follicular lymphoma

CA: A CANCER JOURNAL FOR CLINICIANS, Vol. 65, Iss. 1, 2015-01 ,pp. : 1-2

John Wiley & Sons Inc

Access to resources Recommend Favorite